Aktienanalyse zu Mangoceuticals Inc (MGRX)MGRXMangoceuticals Inc

Mangoceuticals, Inc. is focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx and is also focused on wellness solutions. It is advancing its proprietary antiviral compound MGX-0024. The Company offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. It has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Mangoceuticals Inc is not a strong buy right now due to its current price of $0.40, which is down 52.87% year-to-date, and an RSI of 42.097 indicating it is nearing oversold territory. The recent surge of 42.12% in stock price due to TRT sales growth is promising, but the overall trend shows a significant decline of 82.04% over the past year, suggesting caution. The main risk is the company's negative net income of -1,312,653 USD in Q2 2026, which reflects ongoing financial struggles.